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visit. Baseline subretinal fluid was associated with better vi-
sual outcomes (p = 0.001). Results of combination treatment 
with intravitreal ranibizumab and PDT did not significantly 
differ from ranibizumab monotherapy.  Conclusion: Modest 
functional outcomes can be expected from the long-term 
treatment of RAP lesions in clinical practice, most likely due 
to the advent of GA. Baseline subretinal fluid positively cor-
related with final BCVA.  © 2015 S. Karger AG, Basel 
 Introduction 
 Retinal angiomatous proliferation (RAP), also known 
as type 3 neovascularization, is a well-recognized neovas-
cular phenotype of age-related macular degeneration 
(AMD), accounting for 12–15% of its exudative form in 
Caucasians  [1] . The angioproliferative process associated 
with RAP diverges from other neovascular membranes, 
as it is believed to start deeply within the retina  [2–6] . 
Yannuzzi et al.  [7] first classified RAP lesions into three 
stages according to clinical and angiographic findings: 
stage 1, intraretinal neovascularization; stage 2, intrareti-
nal plus subretinal neovascularization, and stage 3, cho-
roidal neovascularization.
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 Abstract 
 Purpose: To evaluate the long-term efficacy of ranibizumab 
in the treatment of retinal angiomatous proliferation (RAP) 
and to identify predictors of functional outcome.  Methods: 
Retrospective case series comprised 79 eyes of 68 consecu-
tive patients with RAP followed up  ≥ 36 months. Primary 
end-points were best-corrected visual acuity (BCVA) and 
central macular thickness (CMT) variation at 36 months and 
at the last visit.  Results: Mean follow-up time was 59.8 ± 16.0 
months. All eyes were treated with pro re nata ranibizumab, 
with (n = 33) or without (n = 46) photodynamic therapy 
(PDT). Stabilization or improvement in BCVA was observed 
in 50.6% of the patients at 36 months, and in 40.5% at the 
end of the follow-up, where 20.3% preserved reading vision. 
A significant decrease in CMT was observed at 36 months
(p < 0.001), but not at the end of the follow-up. Geographic 
atrophy (GA) was present in 59.5% of the eyes at the final 
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 The advent of optical coherence tomography (OCT), 
fundus autofluorescence and infrared imaging allowed 
for a better characterization of the structural changes as-
sociated with the disease, such as drusen, reticular pseu-
dodrusen, inner and outer retinal cysts, pigment epithe-
lium detachment (either with or without fibrovascular 
material), subretinal fluid and geographic atrophy (GA) 
 [8, 9] . The prognostic value of some of these features has 
been highlighted in several publications  [8, 10–12] .
 RAP has historically been coined a bilaterally aggres-
sive disease with a poor natural history and high relapse 
rates. While several treatment approaches proved unsuc-
cessful in the past  [13–17] , the blockage of vascular endo-
thelium growth factor (VEGF) has substantially changed 
the prognosis of this condition. Reports on intravitreal 
(IV) ranibizumab, either in monotherapy or with con-
comitant photodynamic therapy (PDT), have underlined 
the responsiveness of RAP lesions to both treatment mo-
dalities  [18–21] . However, standard protocols for the 
management of the disease are currently not available  [1] , 
and published data are limited to small case series with 
short follow-up periods  [18–21] .
 The purpose of this study was to evaluate the long-
term efficacy and safety of IV ranibizumab in eyes with 
RAP treated in a tertiary care hospital and to identify pre-
dictive factors of functional outcome.
 Materials and Methods 
 Population 
 Retrospective case series included 79 eyes of 68 consecutive 
RAP patients followed from January 2007 to October 2011. Inclu-
sion criteria were a confirmed diagnosis of RAP based on clinical 
and angiographic findings and  ≥ 36 months of follow-up after the 
first IV ranibizumab injection. Patients previously on other AMD 
treatment formulations, those with a positive past medical history 
for acute cardiovascular events and those with ophthalmologic 
conditions likely to jeopardize the clinical assessment were exclud-
ed from this analysis. Baseline best-corrected visual acuity (BCVA) 
was not set as an inclusion or exclusion criterion. Before inclusion, 
all patients signed an informed consent and the study was con-
ducted according to the tenets of the Declaration of Helsinki.
 Clinical Assessment and Imaging 
 Baseline assessment included a complete ophthalmologic ex-
amination complemented with color fundus photography (CFP; 
 fig. 1 ), fluorescein angiography, indocyanine green angiography 
and OCT. BCVA was measured according to a standardized re-
fraction protocol using an Early Treatment Diabetic Retinopathy 
study (ETDRS) chart. Visual enhancement and deterioration were 
defined as an increase or decrease  ≥ 5 ETDRS letters from baseline, 
respectively. A stabilized BCVA encompassed any oscillation be-
tween those values. Reading vision was classified as a BCVA 
 ≥ 20/70 (Snellen visual acuity chart) according to the World Health 
Organization criteria. For standardization purposes, we will refer 
to this reading vision as an ETDRS equivalent of  ≥ 60 letters. RAP 
stage at diagnosis was categorized by a senior retina specialist ac-
cording to the three angiogenic stages defined by Yannuzzi et al. 
 Fig. 1. Top left: baseline CFP of one of the 
RAP patients included in the study. Note 
the paucity of drusen, the presence of pig-
mentary changes in the macular area as 
well as an apparently thickened retina. 
Baseline time-domain OCT of this eye 
shows intraretinal fluid and the presence of 
a retinal pigment epithelium detachment 
(bottom left). On the right, central GA can 
be seen both in infrared imaging (top) and 
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 [7] . Before 2009, all OCT images were obtained using the high-
resolution 6-radial line protocol of Stratus ® OCT (Carl Zeiss Med-
itec, Dublin, Calif., USA). With the availability of spectral-domain 
OCT, all further images were acquired using the Spectralis ® OCT 
(Heidelberg Engineering, Heidelberg, Germany). Since both spec-
tral- and time-domain OCT examinations were performed, time-
domain OCT grading was calibrated to spectral-domain OCT to 
minimize potential measurement bias  [22] . Identification of GA 
was based on the presence of >1 patch of >250 μm in the lengthiest 
linear dimension in CFP within the macula, evidencing >1 of these 
additional characteristics: sharply delimited boundaries, excavat-
ed or punched-out appearance on stereoscopy, enhancement of 
the choroidal circulation in CFP and correlation with OCT find-
ings. BCVA and central macular thickness (CMT) were recorded 
during every visit. Adverse events possibly related with IV ranibi-
zumab administration were registered.
 Treatment 
 All patients were treated with IV ranibizumab (Lucentis ® ; No-
vartis International AG, Basel, Switzerland), 0.5 mg/0.05 ml, in a 
nonloading dose pro re nata (PRN) regimen, with (n = 33) or with-
out (n = 46) associated PDT with verteporfin (Visudyne ® ; Novar-
tis International AG). Decision on retreatment was based on a de-
crease in BCVA  ≥ 1 ETDRS line and/or OCT findings, specifically 
the presence of retinal pigment epithelium detachment, hemor-
rhage, and intra- or subretinal fluid. Each IV injection was per-
formed 3.5–4.0 mm posterior to the corneal limbus using a 
30-gauge needle after instillation of topical anesthesia and 5% po-
vidone-iodine solution in the fornix. Prophylaxis of endophthal-
mitis was achieved with topical quinolone q.i.d. 4 days before and 
4 days after the IV injection. PDT was performed only in cases 
included until December 2009, and discontinued after an interme-
diate analysis showed no additional benefit versus PRN IV ranibi-
zumab monotherapy. When treating bilateral RAP, IV ranibizum-
ab or PDT were performed on separate days. 
 End-Points 
 BCVA and CMT variation at 36 months and at the end of the 
follow-up were defined as primary end-points of IV ranibizumab 
efficacy.
 Statistical Analysis 
 All statistical analyses were performed using STATA ® version 
12.1 (StataCorp LP, College Station, Tex., USA), and p  ≤ 0.05 was 
considered statistically significant. Categorical variables were 
summarized as frequencies and percentages, and numerical vari-
ables as means ± SD and minimum/maximum. The Shapiro-Wilk 
test was used to assess the normal distribution of continuous vari-
ables. The χ 2 test or Fisher’s exact test was performed to appraise 
associations between categorical variables, and the Student t test 
for associations involving independent and paired samples. Mann-
Whitney, Wilcoxon, ANOVA and Kruskal-Wallis tests were ap-
plied for associations between continuous variables.
 Results 
 Demographics 
 Seventy-nine eyes from 68 individuals were analyzed; 
45 of the patients were females. Mean age at diagnosis was 
78.9 ± 7.0 years (range: 60–92 years). Follow-up lasted at 
least 3 years: 72.2% (n = 57) had  ≥ 4 years and 48.1% (n = 
38)  ≥ 5 years, with a mean follow-up of 59.8 ± 16.0 months. 
 RAP Stage and Neovascularization of the Fellow Eye 
 According to the classification proposed by Yannuzzi 
et al.  [7] , 13 (16.5%) eyes were classified at baseline as 
stage 1, 31 (39.2%) as stage 2 and 35 (44.3%) as stage 3. 
Stage 3 eyes presented a significantly lower baseline 
BCVA when compared to eyes in stage 1 (p = 0.022) or 
stage 2 (p = 0.010). However, no substantial differences 
were noticed in the total number of IV ranibizumab injec-
tions (p = 0.220) or presence of GA at the final visit (p = 
0.206) among the different RAP stages. Thirty-two 
(41.5%) patients had unaffected fellow eyes at baseline, 
and 17 (51.3%) of them developed neovascularization 
during the follow-up.
 Visual Acuity 
 BCVA progression during follow-up and visual out-
come at 36 months and at the end of the follow-up are 
depicted in  figures 2  and 3 . At diagnosis, 20.3% (n = 16) 
of the patients were legally blind ( ≤ 35 ETDRS letters) and 
50.6% (n = 40) presented criteria for low visual acuity 
(<60 ETDRS letters). A significant increase in BCVA was 
observed at the 3rd month compared to baseline (p = 
0.001). At 36 months, 31.6% of the eyes had improved 
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in 19.0% there was no significant change (variation <5 
ETDRS letters). During the whole length of follow-up, 
BCVA improved in 22.8%, decreased in 59.5%, and re-
mained stable in 17.7%. At the last visit, 53.2% (n = 42) of 
the patients were characterized as legally blind, and 26.6% 
(n = 21) were in the low vision range, whereas 20.3% (n = 
16) preserved a BCVA  ≥ 60 ETDRS letters. Thirty-seven 
eyes (46.8%) lost  ≥ 15 letters during the whole follow-up. 
Mean BCVA overall variation concerning the first and 
last visits was –14.0 ± 22.7 (p < 0.001). No significant dif-
ferences in the visual outcome were seen between eyes 
treated with IV ranibizumab monotherapy and eyes 
treated with IV ranibizumab plus PDT (p = 0.831). No 
significant correlation was found between the total num-
ber of IV ranibizumab and the BCVA variation at 36 
months (p = 0.966) and at the end of the follow-up (p = 
0.721 compared to baseline).
 OCT Parameters 
 Mean CMT progression during follow-up is depicted 
in  figure 4 . There was a significant decrease in this param-
eter after 3 and 36 months compared to baseline (p < 
0.001 for both cases). Even though final CMT was still 
inferior to the mean baseline values, this reduction was 
not statistically significant (–27.1 ± 163.3 μm, p = 0.095). 
Sixty-two eyes (78.5%) had intra- and/or subretinal fluid 
at presentation. This number decreased to 58.2% at the 
end of the follow-up. A positive correlation was found 
between the presence of subretinal fluid at presentation 
and better final BCVA (p = 0.001). From the 79 eyes eval-
uated, 47 (59.5%) ultimately developed areas of either fo-
veal or extrafoveal GA. No correlation was noticed be-
tween the presence of GA in the final visit and final or 
baseline BCVA, follow-up time or total IV ranibizumab.
 Treatment Parameters and Adverse Effects 
 The mean number of IV ranibizumab injections per 
patient was 9.2 ± 5.7, representing a mean of 2.2 ± 1.2 in-
jections/patient/year during the whole follow-up period. 
The highest IV ranibizumab/year ratio was observed in 
the first 2 years of follow-up: 3.4 ± 1.5 in the 1st year and 
2.2 ± 1.4 in the 2nd. Thirty-four patients were treated with 
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 Fig. 3. Visual outcomes at 36 months and 
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derwent IV ranibizumab monotherapy. Between these 
two groups, no differences regarding visual outcome was 
found either at 36 months (p = 0.816) or at the end of the 
follow-up (p = 0.699); sub- or intraretinal fluid at the last 
visit (p = 0.467 and p = 0.377, respectively); GA develop-
ment (p = 0.570), or total number of IV ranibizumab in-
jections (p = 0.929) during the whole length of the follow-
up. Nine patients (13.2%) experienced vascular adverse 
effects after starting IV ranibizumab therapy: 7 had isch-
emic strokes (10.3%). The remaining 2 patients suffered 
from acute myocardial infarction and pulmonary throm-
boembolism, respectively. All these patients had at least 
one systemic cardiovascular risk factor to trigger the in-
cident.
 Discussion 
 RAP is believed to have a worse natural history than 
other subtypes of exudative AMD  [23] . Over the past 
years, the success rate of the various available treatments 
has been inconsistent. Nevertheless, some authors report 
relative stabilization of the disease with treatment, either 
PDT  [13, 14] or IV ranibizumab  [18, 19, 21] . PDT was 
combined with IV ranibizumab  [18, 24] or even IV triam-
cinolone  [18] . The maximal follow-up of studies on RAP 
treatment with IV ranibizumab with/without PDT was 3 
years  [18–21] and small sample sizes were small  [18, 19, 
24] . To our knowledge, this study combines the longest 
follow-up (59.8 ± 16.0 months, on average) with the larg-
est sample size (n = 79) on RAP lesions treated with IV 
ranibizumab published to date.
 Our clinical practice results demonstrated that PRN 
IV ranibizumab regimens can be effective in maintaining 
or improving BCVA in about half (50.6%) of the treated 
eyes at 36 months, and in 40.5% after a mean follow-up 
of approximately 5 years. Remarkably, in about one fifth 
of our population reading vision was preserved at the last 
visit. Other studies reported better BCVA results at 2- or 
3-year follow-ups  [18–20, 24] . One possible explanation 
could be that the use of anti-VEGF agents in clinical prac-
tice rather than in a clinical trial setting  [18, 20] may lead 
to poorer than expected BCVA outcomes: the depen-
dence on the resources and agenda of the clinical center 
may delay the initiation of treatment, protracting the gap 
between injections and subsequent follow-up. The treat-
ment regimen – PRN – and other limitations inherent in 
a clinical practice setting may also have influenced our 
end-points, and the mean number of injections/patient/
year (2.2 ± 1.2) also suggests that our patients may have 
been undertreated. Furthermore, motivation may differ 
in a clinical trial, as the expectations of a promising new 
treatment modality may increase patient compliance for 
the scheduled visits.
 No differences in visual outcome were noticed be-
tween the IV ranibizumab and IV ranibizumab plus PDT 
groups. Our results are in agreement with the ones re-
ported by Rouvas et al.  [18] , who investigated three treat-
ment arms: IV ranibizumab; IV ranibizumab + PDT, and 
IV triamcinolone + PDT. Patients were followed for 36 
months and presented similar functional outcomes.
 In our analysis, a significant reduction in CMT was 
observed at 3 months, along with a BCVA improvement, 
and exudation from RAP lesions seems to have regressed 
swiftly soon after treatment commencement. Other re-
ports also underline this favorable initial response of RAP 
lesions to treatment  [19, 24, 25] . The decrease in CMT 
between baseline and the 36-month follow-up was still 
statistically significant in our population. Rouvas et al. 
 [18] also reported significant mean decreases in CMT at 
3 and 36 months (last follow-up). In a recent study by Cho 
et al.  [21] , a significant decrease in mean CMT was de-
tected after 24 months. In our cohort, CMT did not sig-
nificantly differ between the last visit and baseline values. 
This might be explained by our longer mean follow-up 
time, since the treatment seems to acquire some degree of 
tachyphylaxis after the initial response. The high percent-
age of eyes with macular fluid in the final OCT (57.3%) 
may be a consequence of this effect, which may reflect the 
final CMT values.
 Those patients whose baseline OCT presented subret-
inal fluid experienced better visual outcomes. According 
to Einwallner et al.  [10] , the subretinal fluid plays a role 
in the prognosis of an exudative lesion because it also re-
flects its activity. These results suggest that a substantial 
part of the pathology of AMD is related to inflammatory 
processes. Ahlers et al.  [26] also came to the conclusion 
that subretinal fluid correlated well with an improvement 
in BCVA, as well as with the time course of functional 
recovery. According to these authors, the relationship be-
tween subretinal fluid and blood-retina barrier function 
breakdown may explain these findings, and it may be an 
important parameter when defining retreatment criteria 
in the future. Interestingly, a recent study  [27] conducted 
in patients enrolled in CATT (Comparison of AMD 
Treatments Trials) found that smaller volumes of sub-
retinal fluid are correlated with a higher probability of GA 
development. Even though this was not observed in our 
cohort, 27 eyes (34.2%) presented with some degree of 






















   
   
   
   
   
   
   
   

























it (59.5%). McBain et al.  [28] reported GA development 
in 53% (n = 35) of RAP eyes, independently of the treat-
ment chosen (IV anti-VEGF and/or PDT), a result that 
supports our findings. The aforementioned CATT re-
search group paper  [27] also focused on the risk factors 
for the development of GA and found that the RAP sub-
type of AMD accounted for a 1.69-fold risk of GA devel-
opment. The high prevalence of GA in RAP could be ex-
plained by decreased choroidal filling in these eyes  [29] , 
thus leading to a near-ischemia status. This concept also 
supports the theory of an intraretinal vascular response 
in RAP, with budding of outward-growing retinal vessels.
 This study has several limitations. Its retrospective na-
ture prevents us from controlling variables. For example, 
follow-up visits should take place at each month but, due 
to agenda issues, this period of time was seldom respect-
ed. A higher number of patients would allow a broader 
analysis of GA epidemiology, which might yield conclu-
sions with more statistical power. We do believe, how-
ever, that these limitations have otherwise a minor impact 
on our results, given our population’s size and follow-up 
length.
 In conclusion, our long-term follow-up on PRN IV ra-
nibizumab for the treatment of RAP lesions in clinical 
practice has shown that  ∼ 40% of the eyes had stable or 
improved BCVA at the end of our long-term follow-up, 
and about one fifth of the individuals preserved reading 
vision. Nevertheless, about 60% of the patients presented 
with some degree of GA at the last visit. The presence of 
subretinal fluid at baseline was found to positively corre-
late with a favorable visual outcome, thus appearing to be 
an important prognostic factor for functional improve-
ment.
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